Update: Replacement information about our BDNF, CCL22 and Neurofascin assays
We previously informed customers about technical issues reported for three of our protein assays. As stated previously, our R&D department have worked hard to develop suitable and relevant replacement assays, and these have now been implemented. The details of the affected assays and their replacements in the different panels are shown below:
Brain-derived neurotrophic factor (BDNF) – Uniprot ID P23560
Panel = Olink® NEUROLOGY
– This assay was replaced by Microtubule-associated protein Tau (MAPT) – Uniprot ID P10636. Consistent with the biology of this protein, our Tau assay is priimarily designed for use with CSF or microdialysis fluid samples.
Panel = Olink® INFLAMMATION
– This assay was replaced by T-cell surface glycoprotein CD8 alpha chain (CD8A) (Uniprot P01732).
Neurofascin (NFASC) – Uniprot ID O94856
Panel = Olink® DEVELOPMENT
– This assay was replaced by Ectonucleotide pyrophosphatase/phosphodiesterase family member 2, also known as Autotaxin (ENPP2) – Uniprot ID Q13822
C-C motif chemokine 22 (CCL22) – Uniprot ID O00626
Panel = Olink® CARDIOVASCULAR III
– This assay was replaced by Platelet glycoprotein VI (GP6) – Uniprot ID Q9HCN6
Again, we apologize sincerely for this highly unusual technical issue with these specific assays, and any inconvenience it may have caused. As a company that prides itself on the quality of our products and our transparency with customers, please be assured that we will do everything in our power to ensure that this issue is resolved as quickly as possible, and to avoid such problems from occurring in the future.
If you have any further questions, please do not hesitate to contact us at firstname.lastname@example.org